New drug ENERGI-F705 takes first step: safety check in 24 volunteers
NCT ID NCT07650383
First seen Jun 17, 2026 · Last updated Jun 20, 2026 · Updated 2 times
Summary
This early-phase trial tested the safety and tolerability of a single dose of ENERGI-F705 tablets in 24 healthy adults aged 18 to 44. Participants were randomly assigned to receive either a 60 mg or 120 mg dose of the drug or a placebo (vehicle control). The study measured side effects and how the drug moves through the body, but it was not designed to test any treatment effect.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTH ADULT SUBJECTS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Taipei Medical University Hospital
Taipei, Taiwan
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ENERGI-F705 tablets
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.